BioCryst Pharmaceuticals Inc
BCRX7.290USD
+0.160+2.24%
Close 12/18, 16:00（ET）Quotes delayed by 15 min
1.53BMarket Cap
LossP/E TTM
BioCryst Pharmaceuticals Inc Earnings Date
Period
FY2024 Earnings Date
Revenue(YoY)
450.71M
36.00%
EPS(YoY)
-0.43
63.52%
Analyst Rating
BUY
2025-12-09
Financial Indicators
EPS
Revenue
Net Profit
Net Margin
Gross Margin
Debt to assets ratio
ROE
ROA
Relevant data have not been disclosed by the company yet.
Income Statement
Revenue
Operating profit
Net Profit
Relevant data have not been disclosed by the company yet.
Balance Sheet
Current assets
Total current liabilities
Total assets
Total liabilities
Total equity
Relevant data have not been disclosed by the company yet.
Cash Flow Statement
Net operating income
Net investment
Net financing
Relevant data have not been disclosed by the company yet.
FAQs
What is the total revenue of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its total revenue reached 450.71M, with a year-on-year change of 36.00%.
What is the Earnings Per Share (EPS) of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its Earnings Per Share (EPS) was -0.430, with a year-on-year change of 63.52%.
What is the net income of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its net income was -88.88M, with a year-on-year change of 60.77%.
What is the net margin of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its net profit margin was -19.72%, with a year-on-year change of 71.15%.
What is the gross margin of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its gross margin was 97.23%, with a year-on-year change of -1.38%.
What is the debt-to-asset ratio of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its debt-to-asset ratio was 169.76%, with a year-on-year change of 4.57%.
What is the Return on Equity (ROE) of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its Return on Equity (ROE) was --, with a year-on-year change of --.
What is the Return on Assets (ROA) of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its Return on Assets (ROA) was -17.65%, with a year-on-year change of 58.45%.
What is the operating profit of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its operating profit was -2.54M, with a year-on-year change of 97.51%.
What are the current assets of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its current assets were 421.97M, with a year-on-year change of -14.92%.
What are the total assets of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its total assets of BioCryst Pharmaceuticals Inc were 490.42M, with a year-on-year change of -5.13%.
What are the total liabilities of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its total liabilities of BioCryst Pharmaceuticals Inc were 966.35M, with a year-on-year change of -0.63%.
What is the total equity of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its total equity of BioCryst Pharmaceuticals Inc was -475.93M, with a year-on-year change of -4.48%.
What is the net operating income of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its net operating income of BioCryst Pharmaceuticals Inc was -88.88M, with a year-on-year change of 60.77%.
What is the net investment of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its net investment of BioCryst Pharmaceuticals Inc was 52.59M, with a year-on-year change of 140.00%.
What is the net financing of BioCryst Pharmaceuticals Inc?
According to BioCryst Pharmaceuticals Inc's FY2024 earnings report, its net financing of BioCryst Pharmaceuticals Inc was -5.76M, with a year-on-year change of -117.73%.
